June's AI-picked stock updates now live. See what's new in Tech Titans, up 28.5% year to date.Unlock Stocks

Clover Health Investments And 2 Other Stocks Under $1 Insiders Are Buying

Published 21/05/2024, 13:40
© Reuters.  Clover Health Investments And 2 Other Stocks Under $1 Insiders Are Buying
CLOV
-

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

The Dow Jones index closed lower by 0.5% on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

MultiPlan

  • The Trade: MultiPlan Corporation (NYSE:MPLN) Director Anthony Colaluca Jr bought a total of 160,000 shares at an average price of $0.60. To acquire these shares, it cost around $96,000.
  • What's Happening: On May 8, MultiPlan posted a GAAP loss of 83 cents per share.
  • What MultiPlan Does: MultiPlan Corp is a provider of data analytics and technology-enabled solutions designed to bring affordability, efficiency, and fairness to the U.S. healthcare industry.
Fresh Tracks Therapeutics
  • The Trade: Fresh Tracks Therapeutics, Inc. (OTC:FRTX) 10% owner Exploration Capital, LLC acquired a total of 74,565 shares at an average price of $0.92. To acquire these shares, it cost around $68,592.
  • What's Happening: The company's stock gained around 16% over the past six months.
Clover Health Investments

  • The Trade: Clover Health Investments, Corp. (NASDAQ:CLOV) Director Anna U Loengard acquired a total of 27,085 shares at an average price of $0.94. The insider spent around $25,672 to buy those shares.
  • What's Happening: On May 7, Clover Health Investments reported better than expected first-quarter financial results.
  • What Clover Health Investments Does: Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant.
Read More: Jim Cramer Says This Materials Stock Is A ‘Great Spec,’ Plus He Recommends Buying Abercrombie & Fitch

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.